Polar Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Polar Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$14.6M	Buy	100,000 +25,000	+33%	+$3.55M	0.11%	161
2020 Q2	$11.1M	Sell	75,000 -75,000	-50%	-$10.1M	0.1%	165
2020 Q1	$16.3M	Buy	150,000 +35,000	+30%	+$4.04M	0.18%	141
2019 Q4	$13.2M	Buy	115,000 +5,000	+5%	+$498K	0.12%	181
2019 Q3	$8.85M	Sell	110,000 -89,372	-45%	-$7.07M	0.08%	207
2019 Q2	$14.5M	Sell	199,372 -5,645	-3%	-$433K	0.13%	166
2019 Q1	$19.2M	Sell	205,017 -89,270	-30%	-$7.47M	0.18%	154
2018 Q4	$21.5M	Buy	294,287 +50,000	+20%	+$3.85M	0.23%	130
2018 Q3	$21.4M	Buy	244,287 +29,287	+14%	+$2.95M	0.18%	148
2018 Q2	$21.2K	Sell	215,000 -226,232	-51%	-$22.4M	0.13%	150
2018 Q1	$52.6M	Sell	441,232 -75,000	-15%	-$9.67M	0.53%	62
2017 Q4	$65.6M	Buy	+516,232	New	+$64.9M	0.68%	31
2015 Q2	–	Sell	-6,857	Closed	-$716K	–	286
2015 Q1	$716K	Buy	6,857 +487	+8%	+$49.4K	0.01%	257
2014 Q4	$618K	Sell	6,370 -4,586	-42%	-$425K	0.01%	256
2014 Q3	$856K	Buy	10,956 +6,198	+130%	+$400K	0.02%	238
2014 Q2	$301K	Buy	+4,758	New	+$283K	0.01%	259
2013 Q3	–	Sell	-419,830	Closed	-$13M	–	258
2013 Q2	$13M	Buy	+419,830	New	+$11.2M	0.45%	78

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Polar Capital's ALNY Position: Q3 2020 in Review

Polar Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 33% in Q3 2020, buying an estimated $3.55M and bringing the position to 100,000 shares worth $14.6M. The position accounts for 0.11% of the portfolio, ranked #161.

Polar Capital first reported a position in ALNY in Q2 2013 and has held it in 17 quarters since. The position peaked at $65.6M in Q4 2017. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

Polar Capital held 100,000 shares of Alnylam Pharmaceuticals worth $14.6M as of Q3 2020.
Polar Capital bought 25,000 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $3.55M.
Alnylam Pharmaceuticals made up 0.11% of Polar Capital's portfolio in Q3 2020, its #161 holding.
Polar Capital first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Polar Capital's Alnylam Pharmaceuticals position peaked at $65.6M in Q4 2017.
356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.